semaglutide news october 2025 compounded crackdown fda compounding november Recently, the U.S. send letters to telehealth companies over The FDA announced plans to – Medicare will negotiate Novo's GLP-1

as of May 2026 is clinical trial enrollment FDA-approved alternatives exist (semaglutide, tirzepatide) with established compounding and dosing pathways and substantial clinical data Self-sourcing research peptides for human use is not safe and carries identity, purity, and contamination risks If you are a clinician: Patient questions about retatrutide source verification are increasing

Additionally, these studies can contribute to further elucidating the mechanism by which GLP-1RAs act and if they possess anti-inflammatory effects independent of glycemic control and weight reduction

That is why screening and dose planning matter

Ellagic acid protects against diabetes-associated behavioral deficits in rats: possible involved mechanisms

But its important to understand that these supplements most always do not have the same level of scientific backing or efficacy as prescription GLP-1 agonists. Read the Glamour article Learn more about Dr